Raymond James reiterates Strong Buy on Taysha Gene Therapies stock By Investing.com

Raymond James reiterated a Strong Buy and $13 price target on Taysha (TSHA), while the stock trades at $4.58 (market cap $1.25B) after a 143% one‑year move. The firm expects 6‑month Part B REVEAL data by end‑2026, a BLA filing in H1 2027 and approval/launch in Q4 2027, and forecasts revenue of $92.2M (2027), $284.0M (2028), $545.6M (2029) and $846.1M (2030). Taysha reported a widened FY2025 net loss of $109.0M ($0.34/sh) versus $89.3M ($0.36) prior year, highlighting ongoing cash burn despite program progress.

Analysis

A positive narrative around an upcoming clinical/regulatory path materially re-rates mid-stage gene therapy names, but the true winners are the capacity and commercialization nodes — CDMOs that can scale AAV vector production and specialty rare-disease commercial partners with payer access. Approval or convincing pivotal data will likely create a step-change in demand for fill/finish and vector manufacturing capacity, tightening lead times and raising outsourced pricing for the next 18–36 months, which benefits scaled CDMOs while increasing costs for late movers.

Primary downside is binary clinical/regulatory risk concentrated in the next 6–18 months; CMC comparability and reagent/manufacturing scale are common non-clinical failure modes that can delay filings even after positive clinical readouts. Separately, the small-patient-base economics for rare-disease gene therapies invite complicated reimbursement constructs (outcomes-based contracts, annuity payments), so valuation capture depends on payor demonstration of durable benefit over multiple years, not just single-time approvals.

Market positioning today appears to price a favorable path rather than to-in-the-weeds operational execution; that asymmetry suggests structured exposure is superior to outright directional exposure. If data surprise positively, acquirers hunting for de-risked platforms will surface quickly — creating a plausible M&A exit within 12–36 months — but absent that de-risking, cash burn and dilution are the most likely paths to reset value.

Key Decisions for Investors

• Tactical asymmetric long: Buy a 12–18 month TSHA call spread (long-dated OTM call, sell higher strike) to cap premium outlay. Rationale: captures binary upside from positive data/M&A with defined max loss (premium) and 2–4x upside potential if the stock re-rates; risk limited to paid premium.
• Hedged equity exposure: Size a small equity position (1–2% NAV) and buy protective puts 6–12 months to limit downside to a pre-set tolerable loss (~20–30%). Rationale: preserves upside optionality through the clinical window while capping tail risk from negative readouts or dilution.
• Relative-value pair: Go long TSHA vs short XBI (or a small-cap biotech basket) for 6–12 months to isolate idiosyncratic outcome risk. Rationale: if company-specific data is positive, TSHA should outperform sector; if the sector sells off, hedge reduces correlation risk—expect positive alpha if the clinical readout diverges from sector sentiment.
• Volatility play post-data: If the market rallies and IV collapses after a readout, consider selling short-dated calls or call spreads to capture premium decay (trade only if liquidity/IV profile is favorable). Rationale: IV crush is common after binary events; selling premium can harvest that move but carries downside if the fundamental narrative continues to improve.